sponsored
PatientsVille.com Logo

PatientsVille

Hypokalaemia Medical Research Studies

Up-to-date List of Hypokalaemia Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Hypokalaemia Medical Research Studies

Rank Status Study
1 Recruiting Comparison of Enteral Versus Intravenous Potassium Supplementation
Condition: Acute Hypokalemia
Interventions: Drug: Intravenous potassium chloride;   Drug: Oral potassium chloride
Outcome Measures: The efficacy EPR and IVPR for treatment of hypokalemia (measured as change in serum potassium levels in milliequivalent/liter (mEq/L) after potassium replacement;   Comparison of adverse effects after EPR and IVPR.;   Comparison of number of dose/s required to achieve resolution of hypokalemia;   Efficacy of EPR and IVPR for various degrees of severity of hypokalemia for each episode of hypokalemia
2 Recruiting Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B
Condition: Patients With Indications for AmB Treatment
Interventions: Drug: Spironolactone 100mg;   Drug: Spironolactone 200mg;   Drug: Placebo
Outcome Measures: Incidence of hypokalemia ≤3.5mEq/L;   Average potassium supplementation;   Incidence of hyperkalemia;   Acute kidney injury;   Incidence of renal tubular damage;   Incidence of hypomagnesemia
3 Recruiting Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter
Condition: Heterozygous Carriers of Gitelman Syndrome
Interventions: Procedure: Blood sample;   Procedure: Urine sample;   Procedure: Blood pressure
Outcome Measures: Systolic blood pressure evaluated by self-measurement;   Salt balance;   Potassium metabolism;   Lipide metabolism;   Glucose, insulin, HOMA index, pre and post test;   Mineral metabolism;   Renal function;   Vascular function evaluation
4 Recruiting Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.
Condition: Castration-resistant Prostate Cancer
Interventions: Drug: abiraterone acetate;   Drug: prednisone;   Procedure: pre-treatment and progression tumor biopsies;   Genetic: assessment of serum corticosteroid intermediates and ACTH
Outcome Measures: The proportion of participants requiring the addition of prednisone to manage symptoms of persistent or severe mineralocorticoid excess (Hypertension and Hypokalemia).;   Assessment of safety and tolerability associated with AA monotherapy and the addition of prednisone to AA.;   The proportion of participants requiring the addition of prednisone to manage symptoms of severe fatigue.;   Assessment of changes in serum concentrations of corticosteroid intermediates between baseline and subsequent assessment visits.;   Assessment of changes in serum concentrations of ACTH between baseline and subsequent assessment visits.;   Assessment of changes in serum concentrations of androgen (including testosterone, DHT and androgen precursors) between baseline and subsequent assessment visits.;   Assessment of changes in BMI and hemoglobin-A1c between baseline and subsequent assessment visits.;   Assessment of PSA response and duration of PSA response to AA monotherapy.;   Assessment of PSA response and duration of PSA response to addition of prednisone to AA at time of PSA progression on AA monotherapy.;   Assessment of the response of measurable disease and time to progression of measurable disease to AA monotherapy.;   Assessment of response of measurable disease and time to progression of measurable disease to addition of prednisone to AA at time of PSA progression on AA monotherapy.
5 Unknown  Metabolic Syndrome and Insulin Resistance in Primary Aldosteronism
Condition: Primary Aldosteronism
Intervention: Procedure: Glucose tolerance test
Outcome Measure:
6 Unknown  A Translational Approach to Gitelman Syndrome
Condition: Gitelman Syndrome
Intervention: Drug: Hydrochlorothiazide
Outcome Measure: Natriuretic and Chloriuretic Response to a thiaizde
7 Unknown  Natural History of Apparent Mineralocorticoid Excess Syndrome
Condition: Apparent Mineralocorticoid Excess Syndrome
Intervention:
Outcome Measure:
8 Unknown  Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial
Condition: Acute Heart Failure
Interventions: Drug: Furosemide;   Drug: low-dose dopamine + low-dose furosemide
Outcome Measures: 1-year mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure).;   60-day mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure).
9 Recruiting Laparoscopic Adrenalectomy Versus Radiofrequency Ablation
Conditions: Hyperaldosteronism;   Conn Syndrome;   Adrenocortical Adenoma
Interventions: Procedure: Radiofrequency Ablation;   Procedure: Laparoscopic Adrenalectomy
Outcome Measures: Morbidity rate;   Resolution of hyperaldosteronism;   Operative time;   Periprocedural hypertensive crisis;   Mortality rate;   Blood loss;   Analgesic requirement;   Time to resumption of activity;   Resolution of Hypokalaemia;   Blood pressure control;   Hospital stay;   Pain score
10 Recruiting Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
Condition: Prostate Cancer
Interventions: Drug: Abiraterone Acetate;   Drug: Prednisone 5 mg twice daily;   Drug: Prednisone 5 mg once daily;   Drug: Prednisone 2.5 mg twice daily;   Drug: Dexamethasone 0.5 mg once daily
Outcome Measures: Number of participants experiencing neither hypokalemia nor hypertension treatment-emergent adverse events up to Week 24;   Progression Free Survival;   Prostate specific antigen response rate;   Time to prostate specific antigen progression;   Objective response rate;   Time to opiate use for cancer pain;   Time to deterioration in Eastern Cooperative Oncology Group (ECOG) performance score by 1 point;   Number of participants with change in EQ-5D-5L score;   Number of participants with change in Brief Pain Inventory - short form (BPI-SF) score;   Number of participants with change in Functional Assessment of Cancer Therapy - Prostate Cancer (FACT-P) score;   Overall Survival;   Time to next therapy for prostate cancer;   Time to initiation of subsequent chemotherapy;   Treatment duration of subsequent chemotherapy
11 Recruiting Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
Conditions: Unstable Angina;   Coronary Artery Bypass Graft;   Dexmedetomidine;   Lidocaine;   Myocardial Injury;   Arrhythmia;   Blood Electrolyte Balance
Interventions: Drug: Lidocaine infusion;   Drug: Dexmedetomidine infusion
Outcome Measures: Myocardial injury marker;   The blood sodium, potassium, calcium level;   The incidence of arrhythmia during and after the surgery;   Postoperative ICU stay, Hospital stay, Extubation time;   Inotropics use during and after the surgery;   The incidence of hypokalemia
12 Recruiting The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer
Condition: Refeeding Syndrome
Intervention: Dietary Supplement: Low sodium diet
Outcome Measures: Occurence of Refeeding events;   Incidence of infections;   Length of stay;   Amount of days admitted to a Intensive-care unit;   Other complications than infections
13 Recruiting Finding the Optimal Cooling tempeRature After Out-of-HoSpiTal Cardiac Arrest
Condition: Out-Of-Hospital Cardiac Arrest.
Interventions: Device: Target Temperature Management of 34°C;   Device: Target Temperature Management of 32°C;   Device: Target Temperature Management of 33°C
Outcome Measures: Fraction of subjects surviving with good neurologic outcome(modified Rankin Score (mRS) ≤ 3) at 90 days after out-of-hospital cardiac arrest.;   Fraction of subjects with good neurologic outcome (mRS ≤ 3) at discharge after out-of-hospital cardiac arrest;   Identify possible covariates influencing survival with good neurological outcome.;   To assess safety with each target temperature with regard to bleeding, infection, renal impairment, hypokalemia and arrhythmia.
14 Recruiting Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter
Conditions: Atrial Fibrillation;   Atrial Flutter;   Potassium;   Cardioversion
Intervention: Drug: Potassium chloride
Outcome Measures: Cardioversion (time and percentage);   Atrial fibrillation at 3 months follow up visit and during 72 hours ECG-monitoring period.
15 Recruiting Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy
Condition: Kidney Failure, Acute
Interventions: Drug: Sodium bicarbonate;   Drug: Sodium chloride
Outcome Measures: Increase in serum creatinine of 44 micromol/L or by 25% within the first 3 days after surgery.;   Postoperative vasoactive medication, intra-aortic balloon pump, mechanical ventilation, reintubation, reoperation, myocardial infarction, stroke, infection, hypokalemia, dialysis, ICU and hospital length of stay and survival.
16 Available Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease
Condition: Byler Disease
Intervention: Drug: RAVICTI
Outcome Measure:
17 Recruiting Abiraterone Acetate for Castrate Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Abiraterone;   Drug: Prednisone
Outcome Measures: Assessment of AR signaling in CTCs and correlation with response;   Change in number and proliferative fraction of CTCs with abiraterone treatment

These studies may lead to new treatments and are adding insight into Hypokalaemia etiology and treatment.

A major focus of Hypokalaemia research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Hypokalaemia